Cargando…
What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2?
The first SARS-CoV-2 vaccine(s) will likely be licensed based on neutralizing antibodies in Phase 2 trials, but there are significant concerns about using antibody response in coronavirus infections as a sole metric of protective immunity. Antibody response is often a poor marker of prior coronaviru...
Autor principal: | Hellerstein, Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452821/ https://www.ncbi.nlm.nih.gov/pubmed/32875286 http://dx.doi.org/10.1016/j.jvacx.2020.100076 |
Ejemplares similares
-
Immune durability and protection against SARS-CoV-2 re-infection in Syrian hamsters
por: Field, C. J., et al.
Publicado: (2022) -
Sustained neutralising antibodies in the Wuhan population suggest durable protection against SARS-CoV-2
por: Strugnell, Richard, et al.
Publicado: (2021) -
Immune recall improves antibody durability and breadth to SARS-CoV-2 variants
por: Chen, Yuezhou, et al.
Publicado: (2022) -
An intranasal vaccine durably protects against SARS-CoV-2 variants in mice
por: Hassan, Ahmed O., et al.
Publicado: (2021) -
Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants
por: Pegu, Amarendra, et al.
Publicado: (2021)